Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Ascletis and Roche to Develop Hepatitis C Treatment for China

publication date: Apr 15, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ascletis, a two-year-old China pharma startup, will collaborate with Roche to develop a Roche drug candidate for treatment of hepatitis C virus in China. Danoprevir is a protease inhibitor that has shown efficacy in European Phase II tests against HCV genotypes 1b and 4. Aslectis’ first deal was also a liver drug: an RNAi based treatment for liver cancer developed by Alnylam Pharma. More details....

Stock Symbols: (VX: ROG) (NSDQ: ALNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors